| Literature DB >> 36118016 |
Verner Eerola1, Ilkka Helanterä1, Fredrik Åberg1, Marko Lempinen1, Heikki Mäkisalo1, Arno Nordin1, Helena Isoniemi1, Ville Sallinen1.
Abstract
Brain death-induced cytokine storm is thought to harm transplantable organs. However, longer procurement times have been associated with non-inferior or better outcomes in kidney, heart, and lung transplants, while optimal procurement time for liver allografts is unknown. Our aim was to analyze the association of time interval from brain death to organ procurement with liver allograft outcomes in two nationwide cohorts. The association of procurement interval with graft survival and short-term complications was analysed in multivariable models. Altogether 643 and 58,017 orthotopic liver transplantations from brain-dead donors were included from Finland between June 2004 and December 2017 and the US between January 2008 and August 2018, respectively. Median time from brain death to organ procurement was 10.5 h in Finland and 34.6 h in the US. Longer interval associated with better graft survival (non-linearly, p = 0.016) and less acute rejections (OR 0.935 95% CI 0.894-0.978) in the US cohort, and better early allograft function (p = 0.005; Beta -0.048 95% CI -0.085 -(-0.011)) in the Finnish cohort, in multivariable models adjusted with Donor Risk Index, recipient age, Model for End-Stage Liver Disease and indication for transplantation. Progressive liver injury after brain death is unlikely. Rushing to recover seems unnecessary; rest and repair might prove beneficial.Entities:
Keywords: brain death; donor hepatectomy; graft survival; liver allograft function; liver transplant dysfunction; organ allocation; procurement surgery
Mesh:
Year: 2022 PMID: 36118016 PMCID: PMC9472133 DOI: 10.3389/ti.2022.10364
Source DB: PubMed Journal: Transpl Int ISSN: 0934-0874 Impact factor: 3.842
Characteristics and outcomes of liver transplantations in Finland from June 2004 to December 2017 and the US from January 2008 to August 2018.
| Variable | Finland N: 643 | US N: 58 017 | Missing FIN | Missing US |
|---|---|---|---|---|
| Donor | ||||
| Procurement interval, hours | 10.5 (8.6–13.2) | 34.6 (26.2–45.9) | 0 | 0 |
| Donor age, years | 53 (41–61) | 38 (24–52) | 0 | 0 |
| Donor BMI, kg/m2 | 24.5 (22.7–26.9) | 26.1 (22.6–30.4) | 0 | 0 |
| Donor gender, male | 342 (53.2%) | 34,591 (59.6%) | 0 | 0 |
| Donor medical history | ||||
| Hypertension | 170 (26.4%) | 18,403 (31.7%) | 0 | 339 (0.6%) |
| Diabetes | 37 (5.8%) | 5,729 (9.9%) | 0 | 0 |
| Donor cause of death: | 0 | 0 | ||
| Anoxia | 16 (2.5%) | 17,773 (30.6%) | ||
| Cerebrovascular accident | 443 (68.9%) | 18,833 (32.5%) | ||
| Trauma | 163 (25.3%) | 19,985 (34.4%) | ||
| Other | 21 (3.3%) | 1,426 (2.5%) | ||
| Donor Risk Index (DRI) | 1.46 (1.22–1.68) | 1.27 (1.08–1.52) | 7 (1.1%) | 557 (1.0%) |
| Donor organ yield | 3 (3–4) | 3 (3–4) | 0 | 0 |
| More than liver and kidney donor | 258 (40.1%) | 31,664 (54.6%) | 0 | 0 |
| Thoracic organ donor | 204 (31.7%) | 29,806 (51.4) | 0 | 0 |
| Donor cardiac arrest prior to brain death | 98 (15.2%) | 3,868 (6.7%) | 0 | 0 |
| Donor race, caucasian | NA | 44,764 (77.2%) | NA | 0 |
| Recipient | ||||
| Partial/split graft | 55 (8.6%) | 1,465 (2.5%) | 0 | 0 |
| Cold ischemia, hours | 4.9 (4.3–5.7) | 6.1 (4.8–7.8) | 7 (1.1%) | 557 (1.0%) |
| Recipient age at transplantation, years | 52 (37–60) | 56 (47–62) | 0 | 0 |
| Recipient gender, male | 350 (54.4%) | 37,885 (65.3%) | 0 | 0 |
| Retransplantation | 57 (8.9%) | 3,637 (6.3%) | 0 | 0 |
| Combination transplantation, kidney | 28 (4.4%) | 5,917 (10.2%) | 0 | 0 |
| Median waiting time, days | 24 (6–61) | 83 (15–274) | 0 | 0 |
| Usage of MARS | 50 (9.3%) | NA | 105 (16.3%) | NA |
| Anhepatic time, minutes | 57 (51–65) | NA | 6 (0.9%) | NA |
| Total bleeding, litres | 2.5 (1.5–4.5) | NA | 7 (1.1%) | NA |
| MELD at transplantation | 15.2 (10.5–21.4) | 21 (13–31) | 82 (12.8%) | 0 |
| Indication for transplantation | 0 | 10 (0.0%) | ||
| Acute liver disease | 80 (12.4%) | 3,002 (5.2%) | ||
| Chronic liver disease | 463 (72.0%) | 45,924 (79.2%) | ||
| Metabolic liver disease | 22 (3.4%) | 1,767 (3.0%) | ||
| Tumor | 78 (12.1%) | 7,314 (12.6%) | ||
| Primary liver pathology | 0 | 0 | ||
| Acute liver failure | 80 (12.4%) | 2,633 (4.5%) | ||
| Primary sclerosing cholangitis | 108 (16.8%) | 2,496 (4.3%) | ||
| Primary biliary cirrhosis | 50 (7.8%) | 1,335 (2.3%) | ||
| Malignancy | 101 (15.7%) | 10,392 (17.9%) | ||
| Alcoholic liver disease | 104 (16.2%) | 10,730 (18.5%) | ||
| HCV cirrhosis | 16 (2.5%) | 11,983 (20.7%) | ||
| NASH | 19 (3.0%) | 5,857 (10.1%) | ||
| Other | 168 (26.1%) | 12,591 (21.7%) | ||
| Graft survival | 0 | 0 | ||
| 1-year | 91.6% | 88.1% | ||
| 2-year | 87.8% | 83.7% | ||
| 3-year | 85.2% | 80.3% | ||
| 5-year | 80.8% | 74.4% | ||
| 10-year | 71.5% | 59.5% | ||
| 15-year | 55.1% | NA | ||
| Model of Early Allograft Function-score | 3.2 (1.9–4.4) | NA | 7 (1.4%) | NA |
| Intrahepatic biliary stricture | 31 (4.8%) | NA | 2 (0.3%) | NA |
| Anastomotic biliary stricture | 91 (14.2%) | NA | 0 | NA |
| Biliary leak | 18 (2.8%) | NA | 1 (0.2%) | NA |
| Early acute rejection | 152 (23.6%) | 3,102 (5.4%) | 0 | 51 (0.1%) |
| Acute rejection during first year | 231 (35.9%) | 3,418 (14.6%) | 0 | 0 |
| Dialysis after transplantation | 146 (22.7%) | NA | 0 | NA |
| Post-operative kidney injury | 366 (68.0%) | NA | 1 (0.2%) | NA |
| Grade 1 | 151 (28.1%) | |||
| Grade 2 | 88 (16.4%) | |||
| Grade 3 | 127 (23.6%) | |||
| Follow-up time, years | 6.6 (3.3–10.7) | 2.9 (1.0–5.8) | 0 | 0 |
Formula by Feng et al. (12).
Number of organs donated per donor.
Donor donated organs besides liver and kidneys.
Metabolic liver disease by definition of Scientific Registry of Transplant Recipients (e.g., Wilson’s disease, hemochromatosis, alpha-1 antritrypsin deficiency, thyrosinemia, primary oxalosis, hyperlipidemia; does not include nonalcoholic fatty liver disease).
Malignancy in removed liver, indication in some cases has been other (e.g., PSC or alcoholic cirrhosis) prior to transplantation, overrules other primary diagnoses.
Graft survival defined as combination outcome of death or retransplantation.
Sub-cohort of 23,430 patients with sufficient data from 2013 to 2018.
Includes all patients after transplantation.
Acute kidney injury defined by KDIGO guidelines, 104 patients excluded from analysis because of preoperative dialysis.
All values are stated as median (interquartile range) or categorical data as exact number (percentage of all) unless otherwise indicated.
NA, data not available for US cohort.
FIGURE 1Distribution of time from declaration of brain death to organ procurement (procurement interval) in Finnish liver donors from June 2004 to December 2017 and SRTR liver donors from January 2008 to August 2018.
Characteristics of liver transplantations in Finland and the US by tertiles of time between brain death and organ procurement (interval).
| Variable | Finland 6/2004–12/2017 | US 1/2008–8/2018 | ||||
|---|---|---|---|---|---|---|
| Donor | ||||||
| Tertile of procurement interval | 1st < 9.2 h n:214 | 2nd 9.2–12.0 h n:215 | 3rd > 12.0 h n:214 | 1st < 29.0 h n:19,333 | 2nd 29.0–41.3 h n:19,326 | 3rd > 41.3 h n:19,358 |
| Procurement interval, hours | 8.1 (7.2–8.6) | 10.5 (9.9–11.3) | 14.9 (13.2–17.9) | 22.8 (18.2–26.2) | 34.6 (31.8–37.7) | 52.1 (45.9–62.2) |
| Donor age, years | 59 (51–64) | 51 (37–59) | 47 (33–56) | 45 (26–56) | 38 (23–51) | 35 (23–48) |
| Donor BMI, kg/m2 | 24.8 (23.4–27.8) | 24.3 (22.0–26.3) | 24.2 (22.5–26.6) | 26.4 (22.8–30.7) | 26.0 (22.4–30.4) | 26.0 (22.6–30.2) |
| Donor gender, male | 113 (52.8%) | 109 (50.7%) | 120 (56.1%) | 11,136 (57.6%) | 11,548 (59.8%) | 11,907 (61.5%) |
| Donor medical history | ||||||
| Hypertension | 77 (36.0%) | 47 (21.9%) | 46 (21.5%) | 7,343 (38.1%) | 5,939 (30.9%) | 5,121 (26.7%) |
| Diabetes | 21 (9.8%) | 6 (2.8%) | 10 (4.7%) | 2,329 (12.0%) | 1,821 (9.4%) | 1,579 (8.2%) |
| Donor cause of death | ||||||
| Anoxia | 0 (0.0%) | 4 (1.9%) | 12 (5.6%) | 5,668 (29.3%) | 5,823 (30.1%) | 6,282 (32.5%) |
| Cerebrovascular accident | 163 (76.2%) | 143 (66.5%) | 137 (64.0%) | 7,393 (38.2%) | 6,149 (31.8%) | 5,291 (27.3%) |
| Trauma | 44 (20.6%) | 62 (28.8%) | 57 (26.6%) | 5,885 (30.4%) | 6,874 (35.6%) | 7,226 (37.3%) |
| Other | 7 (3.3%) | 6 (2.8%) | 8 (3.7%) | 387 (2.0%) | 480 (2.5%) | 559 (2.9%) |
| Donor Risk Index | 1.52 (1.38–1.77) | 1.42 (1.16–1.65) | 1.35 (1.16–1.52) | 1.33 (1.11–1.61) | 1.26 (1.08–1.52) | 1.22 (1.08–1.47) |
| More than liver and kidney donor | 29 (13.6%) | 84 (39.1%) | 145 (67.8%) | 7,240 (37.4%) | 11,204 (58.0%) | 13,220 (68.3%) |
| Thoracic donor | 12 (5.6%) | 68 (31.6%) | 124 (57.9%) | 6,542 (33.8%) | 10,511 (54.4%) | 12,753 (65.9%) |
| Recipient | ||||||
| Partial/split graft | 11 (5.1%) | 19 (8.8%) | 25 (11.7%) | 312 (1.6%) | 525 (2.7%) | 628 (3.2%) |
| Cold ischemia, hours | 4.74 (4.22–5.70) | 4.93 (4.28–5.70) | 4.95 (4.38–5.68) | 6.0 (4.7–7.7) | 6.3 (5.0–8.0) | 6.0 (4.8–7.7) |
| Recipient age at transplantation, years | 55 (44–60) | 51 (32–60) | 50 (34–59) | 56 (48–61) | 56 (47–62) | 56 (46–62) |
| Recipient MELD at transplantation | 16 (11–23) | 15 (11–21) | 15 (10–20) | 21 (14–30) | 21 (13–30) | 22 (13–33) |
| Liver pathology | ||||||
| Acute liver failure | 31 (14.5%) | 24 (11.2%) | 17 (7.9%) | 952 (4.9%) | 881 (4.6%) | 978 (5.1%) |
| Malignancy | 33 (15.4%) | 36 (16.7%) | 32 (15.0%) | 4,885 (25.3%) | 4,788 (24.8%) | 4,829 (24.9%) |
| PSC | 25 (11.7%) | 39 (18.1%) | 45 (21.0%) | 788 (4.1%) | 799 (4.1%) | 852 (4.4%) |
| Alcoholic liver disease | 44 (20.6%) | 29 (13.5%) | 38 (17.8%) | 3,137 (16.2%) | 3,227 (16.7%) | 3,596 (18.6%) |
| Other | 81 (37.9%) | 87 (40.5%) | 82 (38.3%) | 9,571 (49.5%) | 9,631 (49.8%) | 9,103 (47.0%) |
| Year of Transplant | 2011 (2007–2014) | 2010 (2007–2014) | 2012 (2009–2016) | 2011 (2009–2014) | 2013 (2011–2016) | 2015 (2013–2017) |
| Follow-up time, years | 7.15 (3.97–11.78) | 6.65 (3.38–10.89) | 5.34 (3.11–9.06) | 4.1 (1.3–7.0) | 3.0 (1.0–5.9) | 1.9 (0.6–3.9) |
Formula by Feng et al (12).
Organs donated besides liver and kidneys, categorical.
All values are stated as median (interquartile range) or exact number (percentage of all) unless otherwise indicated.
Outcomes of liver transplantations in Finland and the US by tertiles of time between brain death and organ procurement (interval).
| Variable | Finland 6/2004–12/2017 | US 1/2008–8/2018 | ||||
|---|---|---|---|---|---|---|
| Tertile of procurement interval | 1st <9.2 h n:214 | 2nd 9.2–12.0 h n:215 | 3rd >12.0 h n:214 | 1st <29.0 h n:19,333 | 2nd 29.0–41.3 h n:19,326 | 3rd >41.3 h n:19,358 |
| Graft survival | ||||||
| 1-year | 92.1% | 90.2% | 92.5% | 87.0% | 88.2% | 89.3% |
| 3-year | 84.6% | 83.1% | 87.8% | 78.5% | 80.3% | 82.5% |
| 5-year | 81.4% | 77.0% | 84.4% | 72.6% | 74.7% | 76.5% |
| 10-year | 74.6% | 64.2% | 77.0% | 57.2% | 61.9% | 58.9% |
| 15-year | 57.2% | 46.4% | 66.0% | NA | NA | NA |
| Intrahepatic biliary stricture | 7 (3.3%) | 13 (6.1%) | 11 (5.2%) | NA | NA | NA |
| Anastomotic biliary stricture | 33 (15.4%) | 27 (12.6%) | 31 (14.5%) | NA | NA | NA |
| Biliary leak | 4 (1.9%) | 7 (3.3%) | 7 (3.3%) | NA | NA | NA |
| Discharge time | NA | NA | NA | 10 (7–18) | 10 (7–18) | 11 (7–19) |
| Early acute rejection | 44 (20.5%) | 56 (26.2%) | 52 (24.3%) | 1,116 (5.8%) | 1,012 (5.3%) | 970 (5.1%) |
| Acute rejection during first year | 73 (34.1%) | 84 (39.1%) | 74 (34.6%) | 1,122 (14.4%) | 1,137 (14.6%) | 1,159 (14.8%) |
| MEAF | 3.3 (2.1–4.6) | 3.3 (2.0–4.5) | 2.9 (1.6–4.1) | NA | NA | NA |
| Post-operative dialysis | 25 (14.1%) | 30 (16.7%) | 30 (16.5%) | NA | NA | NA |
| Post-operative kidney injury | 124 (70.5%) | 122 (67.8%) | 121 (66.5%) | NA | NA | NA |
| Difference in creatinine | 57 (18–131) | 40 (14–121) | 45 (15–113) | NA | NA | NA |
In Finnish cohort acute rejection before 30 days and in the US cohort before discharge.
For US in sub-cohort of transplantations performed 2013 onwards (middle-tertile of 33–46 h of procurement interval).
Model for Early Allograft Function (13), median (interquartile range).
AKI requiring dialysis within 7 post-operative days.
Acute kidney injury defined by KDIGO guidelines, grades 1–3. 104 patients (16.2%) were dialysed preoperatively and were excluded from post-operative kidney injury and dialysis analysis.
Difference between highest creatinine in 7 post-operative days and pretransplantation creatinine in mmol/l.
FIGURE 2Odds of acute rejection before discharge by procurement interval from multivariable logistic regression models in the US whole cohort (A) and thoracic organ donors only (B) with 95% confidence intervals in grey.
FIGURE 3Relative hazard of graft loss or death by procurement interval from univariable (A) and multivariable (B) Cox regression models in the Finnish cohort with 95% confidence intervals in grey.
FIGURE 4Relative hazard of graft loss or death by procurement interval from univariable (A) and multivariable (B) Cox regression models in the US cohort with 95% confidence intervals in grey.
FIGURE 5Kaplan-Meier curves with survival tables in Finnish (A) and the US (B) cohort with cases divided by procurement interval tertiles for graphical purposes with 95% confidence intervals in grey.